Nathan Erdmann

[Nathan Erdmann @NerdmannID]

@monsta23 @thecurbsiders @MeredithTrubitt Right back at you @monsta23

[Nathan Erdmann @NerdmannID]

Have seen this from the provider side far too many times. So sorry for you and your family, and thank you for sharing.

[Hina Patel @hinapatelRx]

Diary of a Sad Woman - why I hate COVID. Sun, Oct 15th - my brother picks up my mom who has just spent 2 weeks in Florida staying with my aunt post uncle’s death.  Mom/dad had both attended my uncle’s funeral 2 weeks earlier.  Mom comes back feeling sick.

[Nathan Erdmann @NerdmannID]

So happy for her, it’s been an incredibly tough road.

[WBRC 6 News @WBRCnews]

A COVID-19 patient is at home Monday after spending more than 200 days in the hospital. Her family is calling it a miracle. https://t.co/YQ7gI8ZDzN

[Nathan Erdmann @NerdmannID]

@DrJeanneM @overton_edgar @msaagmd @JoHofmann2 @SonyaHeathMD It’s amazing how fast things have moved forward, but these antibody therapies present so many logistical challenges. Our ability to identify, refer and treat in a very tight window will be really tough, exponentially more so for our more vulnerable populations.

[Nathan Erdmann @NerdmannID]

Catching back up after a Twitter hiatus... Grateful for some phenomenal collaborators and my first corresponding author paper out in JCI!

[Journal of Clinical Investigation @jclinicalinvest]

Just Published @goepfert_paul @NerdmannID @UABSOM: Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection: https://t.co/5a9HydmhgY
#COVID_19 #Immunology

[Nathan Erdmann @NerdmannID]

Great work Jake!

[Jacob Files @JacobFiles93]

Really excited that my first, first-author paper was officially published a few weeks ago! Extremely grateful to @goepfert_paul and @NerdmannID for the incredible mentorship and this opportunity. Also, much thanks to @BoppanaSushma @millieperez_4 and other authors for their help.

[Nathan Erdmann @NerdmannID]

@DrEllenEaton @DoctorRachael Are we on for tomorrow? I can’t remember what the verdict was on scheduling

[Jeanne Marrazzo @DrJeanneM]

If you're caring for or have #COVID19 in greater @cityofbhamal area, consider @UABSOM #research study, led by stellar @UAB_ID team @overton_edgar @goepfert_paul @SonyaHeathMD @NerdmannID @AlisaPeinhardt @AadiaMd -- WE NEED #evidence to treat this plague!

[Savannah Koplon @savannah_koplon]

Drew McDonald was a healthy 29 year old, father of 2 when he came down with COVID-19 in late March. He enrolled in the #remdesivir clinical trial at @UABSOM under @NerdmannID @UAB_ID. Grateful that he shared his story of recovery w/ @UABNews. https://t.co/NNFRTt3VFE

[Nathan Erdmann @NerdmannID]

@jodie_dionne Nice to see a politician articulate empathy and nuance, sadly uncommon.

[Nathan Erdmann @NerdmannID]

@DrLuisO We have not. Admittedly in a data free zone, but CRRT should be able to remove the vehicle without major issue. What is less clear is drug levels, but given remdesivir is metabolized almost exclusively by liver, levels should be similar. Look forward to seeing hard data soon.

[Nathan Erdmann @NerdmannID]

@DrLuisO In consultation with pharmacy and nephrology, the risk of further renal insult is not thought to be high on CRRT.

[Nathan Erdmann @NerdmannID]

@DrLuisO Our strategy has been to not initiate EUA remdesivir with a GFR <15, but for those that have already been started, we have continued to complete a course even if the patient ends up on CRRT.

[Nathan Erdmann @NerdmannID]

@IDJClub Then the surprise: DSMB identified a statistically significant observation, leading to this preliminary report.

[Nathan Erdmann @NerdmannID]

@IDJClub Ya, this doesn’t make sense until you step back and realize how fast things went. The initial assessment was planned for 440 enrollments, but rather than stop additional enrollments, study continued until there were enough completions to fully power study.

[Nathan Erdmann @NerdmannID]

@IDJClub It was GFR <50 for phase I, adjusted for phase II.

[Nathan Erdmann @NerdmannID]

@IDJClub @Cortes_Penfield @unmc Nathan Erdmann md/phd at UAB w/ @TMcCarty2010, where I usually do transplant ID and HIV immunology, but have been involved in all things COVID and am a co-author on the study.

[Caitlin Rivers @cmyeaton]

2001: anthrax
2003: SARS
2009: H1N1
2014: Ebola
2015: Zika
2020: Covid
This pandemic is historic, but health security threats are alarmingly common. We must break the reactive cycle of panic and neglect and prepare our public health and medical systems for the next threat.

[Jeanne Marrazzo @DrJeanneM]

Yes. Amazing @uabsom team who pulled this off with gusto & sweat. Many thanks! @NerdmannID @goepfert_paul @AlisaPeinhardt @UAB_ID @UABPathology @UABNews

[NEJM @NEJM]

In this double-blind RCT in 1063 adults hospitalized with #COVID19, a 10-day course of intravenous remidesivir was superior to placebo in shortening the time to recovery. The estimates of mortality at 14 days were 7.1% in the remdesivir group and 11.9% in the placebo group.